Claritev Corp (formerly MultiPlan) 2024 Annual Report Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2024. Claritev Corporation (formerly MultiPlan Corporation) is a healthcare technology, data, and insights company providing cost management, payment integrity, and analytics solutions to payors, employers, and providers. The company rebranded to Claritev on February 17, 2025, and plans to change its NYSE ticker from "MPLN" to "CTEV" effective February 28, 2025. The company operates as a single reporting segment focused on the U.S. healthcare market.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenues | $930.6 million | $961.5 million |
| Net Loss | $(1,645.8) million | $(91.7) million |
| Adjusted EBITDA | $576.7 million | $618.0 million |
| Operating Cash Flow | $107.6 million | $171.7 million |
| Total Debt (Principal) | $4,565.7 million | $4,600.0 million |
| Cash and Cash Equivalents | $16.8 million | $71.5 million |
| Goodwill | $2,403.1 million | $3,829.0 million |
Note: The 2024 Net Loss includes a non-cash impairment charge of $1.489 billion. Adjusted EBITDA excludes this charge and other non-recurring items.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 3.2% to $930.6 million. Network-Based Services declined 17.1% due to customer attrition, a cyberattack at a major claims clearinghouse disrupting flows, and a strategic shift of revenue to Analytics-Based Services. Analytics-Based Services increased 1.4%, driven by the BST acquisition and the aforementioned shift.
- Significant Impairment: The company recorded a $1.489 billion loss on impairment of goodwill and intangible assets. This was triggered by significant declines in stock price and market capitalization throughout 2024, revised forecasts, and a rebranding initiative that rendered certain trademarks obsolete ($54.5 million).
- Refinancing Costs: The company incurred $63.9 million in transaction costs related to a refinancing transaction consummated in January 2025, which was expensed in 2024.
- Stock Split: A 1-for-40 reverse stock split was effected in September 2024 to regain compliance with NYSE listing standards.
Guidance, Outlook, and Risks
Strategic Outlook (Vision 2030): Management is executing a transformation plan to become a technology and data insights company. Key initiatives include a new subscription revenue model, entry into the provider market, and a digital transformation partnership with Oracle Cloud Infrastructure. The company brands 2025 as "THE TURN" and 2026 as "THE WAY UP."
Recent Refinancing: On January 30, 2025, the company completed a major refinancing, exchanging existing notes and term loans for new first-lien term loans and notes with maturities extending to 2030 and 2031. This transaction incurred approximately $68.8 million in total transaction expenses.
Key Risks:
- Client Concentration: Two clients accounted for 28% and 16% of 2024 revenues, respectively. Loss of these clients would materially impact results.
- Debt and Liquidity: The company carries significant indebtedness (~$4.7 billion including subsequent refinancing). High leverage limits flexibility and increases interest rate risk, though $800 million of variable debt is hedged via interest rate swaps.
- Regulatory Environment: Changes in healthcare laws, including the No Surprises Act (NSA) and mental health parity regulations, create compliance costs and operational complexity.
- Cybersecurity: The company faces risks from data breaches and system disruptions, which could compromise sensitive patient data and disrupt operations.
Investor Verification Checklist
- Impairment Sustainability: Verify if the $1.489 billion impairment charge was a one-time event or if further goodwill impairment is likely given the narrow margin between fair value and carrying value (less than 5%).
- Refinancing Impact: Assess the impact of the January 2025 refinancing on future interest expenses and debt covenants, specifically the new consolidated first-out first lien debt to consolidated EBITDA ratio covenant (2.50 to 1.00).
- Client Retention: Monitor the renewal status of the top two clients, which represent 44% of total revenue.
- Revenue Mix Shift: Track the transition from Network-Based Services to Analytics-Based and Data & Decision Science Services to validate the "Vision 2030" growth strategy.
- Liquidity Position: Confirm the company's ability to service debt obligations given the low cash balance ($16.8 million) and reliance on the revolving credit facility.